BioNTech taps ex-Sobi CEO Oelkers to replace Sahin
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- BioNTech named Guido Oelkers, the former CEO of Swedish biopharma Sobi, as its new CEO, replacing company cofounder Ugur Sahin
- Oelkers will start the role by Feb. 1, 2027, and brings more than 30 years of biopharma experience to BioNTech's leadership team
- Ugur Sahin and his cofounder and wife Özlem Türeci, BioNTech's chief medical officer, announced in March they would depart to lead a new biotech focused on developing mRNA medicines
- Oelkers said he would continue BioNTech's stated ambition of becoming a global company with multiple approved medicines by 2030
- The appointment comes as BioNTech continues a strategic shift away from its Covid-19 vaccine origins toward oncology drug development
Why it matters: The handoff from Sahin — BioNTech's scientist cofounder who built the company's Covid vaccine — to an outside pharma operator like Oelkers formalizes a shift from a pandemic-era mRNA origin story to a broader commercial medicines pipeline, with the company's stated 2030 multi-medicine target now in an outsider's hands.
